Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

I-MAB - American Depositary Shares (NQ:IMAB)

5.770 -0.790 (-12.04%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about I-MAB - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Valneva (NASDAQ:VALN) shares increased by 24.51% to $50.34 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6... 
Via Benzinga
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:... 
Via Benzinga
I-Mab Shares Gain On Licensing Pact For Its Human Growth Hormone In China
I-Mab (NASDAQ: IMAB) has collaborated with Jumpcan Pharmaceutical Group to develop, manufacture, and commercialize eftansomatropin alfa (TJ101) in mainland... 
Via Benzinga
MorphoSys Presents Early Felzartamab Data From Autoimmune Kidney Disease Trial
MorphoSys AG (NASDAQ: MOR) presented interim results from the M-PLACE Phase 1b/2a study with felzartamab at the 2021 Annual Meeting of the American Society of... 
Via Benzinga
Week In Review: MicroTech Medical Staging $245 Million HK IPO For Diabetes Products
MicroTech Medical, a Hangzhou company that offers diabetes monitoring and treatment devices, is conducting a Hong Kong IPO that would raise $254 million at the top of the price range. LianBio has filed... 
Via Talk Markets
Topics Initial Public Offering
I-Mab In Talks With Pharma Giants About Partnership, Stake Sale: Bloomberg
A year after I-Mab (NASDAQ: IMAB) made headlines with its $2.9 billion deal licensing a CD47 drug to AbbVie Inc (NYSE: ABBV), the biotech is reportedly... 
Via Benzinga
Why Are I-Mab Shares Trading Higher On Tuesday?
The Center for Drug Evaluation of China National Medical Products Administration has signed off I-Mab's (NASDAQ: IMAB) IND application to initiate a Phase 2... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) shares increased by 70.28% to $9.11 during Tuesday's pre-market session. The company's market cap stands at $24.5... 
Via Benzinga
I-Mab Stock Joins Rank Of Stocks With RS Ratings Over 90
Looking for the best stocks to buy? Focus on those with rising relative strength such as I-Mab stock, which saw a (RS) Rating upgrade to 93. 
Via Investor's Business Daily
48 Biggest Movers From Friday
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by... 
Via Benzinga
I-Mab Stock Flashes Vital Signs With 89 RS Rating
I-Mab stock had its Relative Strength Rating upgraded from 70 to 89 on Wednesday. Is this biopharma stock on your radar? 
Via Investor's Business Daily
10 Biggest Price Target Changes For Wednesday
Rosenblatt raised Ambarella, Inc. (NASDAQ:AMBA) p... 
Via Benzinga
I-MAB (IMAB) Q2 2021 Earnings Call Transcript
IMAB earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Sonnet BioTherapeutics (NASDAQ:SONN) shares moved upwards by 110.49% to $1.57 during Thursday's regular session. Trading volume for Sonnet BioTherapeutics'... 
Via Benzinga
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
I-Mab Stock Is Trading Lower After Unveiling Mid-Stage Trial Data Of Plonmarlimab In Hospitalized COVID-19 Patients
I-Mab (NASDAQ: IMAB) has announced interim data from its Phase 2/3 study evaluating plonmarlimab (TJM2 or TJ003234) for cytokine release syndrome (CRS) in patients... 
Via Benzinga
58 Biggest Movers From Yesterday
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares climbed 63.7% to close at $1.22 on Thursday after dropping 12% on Wednesday. Sonnet BioTherapeutics recently... 
Via Benzinga
Week In Review: Kumquat Signs $2 Billion US-China Deal With Lilly For Novel Immune Drugs
Kumquat Biosciences announced a $2 billion agreement with a Lilly subsidiary to discover small molecule drugs that stimulate tumor-specific immune responses in cancer patients. Lilly will make a $70... 
Via Talk Markets
I-Mab To Start Testing Alzheimer's Candidate In Human Trials
The FDA has signed off I-Mab (NASDAQ: IMAB) Investigational New Drug (IND) application for Protollin, an Alzheimer's candidate. Brigham and Women's... 
Via Benzinga
62 Biggest Movers From Yesterday
Gainers Flora Growth Corp. (NASDAQ: FLGC) surged 63.1% to close at $8.27. The Miami-based cannabis producer confirmed Tuesday it has signed a non-binding letter of intent to... 
Via Benzinga
Topics Cannabis
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Infinity Pharmaceuticals (NASDAQ:INFI) shares moved upwards by 45.98% to $2.22 during Wednesday's regular session. As of 12:30 EST, this security is trading at... 
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares jumped 59.9% to $2.43. Infinity Pharmaceuticals shares tumbled over 31% on Tuesday after the company highlighted the... 
Via Benzinga
I-Mab Stock Moves Higher As IND For Mid-Stage Efineptakin Cancer Trial Accepted By China
The National Medical Products Administration (NMPA) of China has signed off I-Mab's (NASDAQ: IMAB) IND application to initiate a Phase 2 trial of efineptakin... 
Via Benzinga
Week In Review: Keymed Completes $378 Million IPO In Hong Kong For Antibody Drugs
Keymed Biosciences​​ of Chengdu completed a $378.5 million Hong Kong IPO to develop its portfolio of antibody candidates. The company priced the IPO at the top end of the range, and its shares rose 28%... 
Via Talk Markets
Topics Initial Public Offering
Week In Review: BeiGene Plans $3 Billion IPO On Shanghai STAR Market
BeiGene of Beijing has been approved to stage a $3 billion IPO on the Shanghai Star Stock Exchange. It will be the first Chinese biopharma to be listed in Shanghai, Hong Kong, and the US. 
Via Talk Markets
Topics Initial Public Offering
The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus
Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment. Eli Lilly and Company (NYSE: LLY) stood out among big... 
Via Benzinga
The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Adial Pharmaceuticals (NASDAQ:ADIL 
Via Benzinga
Stocks That Hit 52-Week Highs On Wednesday
This morning 132 companies reached new 52-week highs. Noteworthy Mentions: The largest company by market cap to break to a new 52-week high was NVIDIA (NASDAQ:NVDA... 
Via Benzinga
Stocks That Hit 52-Week Highs On Wednesday
Before 10 a.m. ET on Wednesday, 105 companies hit new 52-week highs. Interesting Facts: Toyota Motor (NYSE:TM) was the largest firm by market cap to set a new 52-... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.